Progress on methotrexate gene polymorphisms in allogeneic hematopoietic stem cell transplantation / 国际儿科学杂志
International Journal of Pediatrics
; (6): 534-538, 2023.
Article
en Zh
| WPRIM
| ID: wpr-989128
Biblioteca responsable:
WPRO
ABSTRACT
Methotrexate(MTX)is one of the main drugs used to prevent graft-versus-host disease(GVHD)after hematopoietic stem cell transplantation, but it can cause a variety of adverse reactions, including severe mucositis, bone marrow suppression and hepatotoxicity.Studies on MTX gene polymorphisms mainly focused on the efficacy and complications of high-dose MTX therapy for various cancers, with relatively few studies on hematopoietic stem cell transplantation.From the perspective of allogeneic hematopoietic stem cell transplantation(allo-HSCT), this article provided a comprehensive review on the pharmacokinetics, complications, and prognosis with MTX gene polymorphisms in allo-HSCT patients, in order to provide clinical reference.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
International Journal of Pediatrics
Año:
2023
Tipo del documento:
Article